1. Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK;2. Department of Oncology/Pathology, Cancer Proteomics Mass Spectrometry, SciLifeLab Stockholm, Karolinska Institutet, Stockholm, Sweden;3. Department of Paediatrics, University of Oxford, Oxford, UK;4. Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Kodaira, Tokyo, Japan;5. Department of Medical, Genetics, School of Human Development Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada;6. MDUK Oxford Neuromuscular Centre, Oxford, UK;7. Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden
Abstract:
Highlights
•Proteomics analysis was performed in two murine models of Duchenne muscular dystrophy (mdx and mdx52) at three ages (8, 16 and 80 weeks) and compared with wild-type controls.
•High-resolution isoelectric focusing liquid chromatography-tandem mass spectrometry enabled the quantification of 4974 proteins in all samples.
•This study has revealed protein signatures of dystrophin deficiency and the progression of dystrophic pathology.
•In contrast, the proteomes of the mdx and mdx52 mice were highly similar.
•Pathway analysis revealed crosstalk between inflammatory, metabolic and muscle growth processes in dystrophic muscle.